{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:10:22Z","timestamp":1784257822417,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T00:00:00Z","timestamp":1590796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T00:00:00Z","timestamp":1590796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prevalences of diabetes mellitus and hypertension, both of which are components of metabolic syndrome, are known to be increased among patients with multiple myeloma (MM), but remain undetermined among patients with smoldering MM (SMM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Changes in various components of metabolic syndrome were investigated during the follow-up of patients with either MM or SMM compared to healthy controls. The data of 153 patients (105 with MM and 48 with SMM) and 138 controls were accessed from our medical center\u2019s records between 2008 and 2015. We analyzed the patients\u2019 data at diagnosis (baseline) and after 1, 3, and 5\u2009years of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with SMM had a significantly higher prevalence of diabetes, hypertension, and dyslipidemia at baseline compared to controls. A multivariate Cox regression analysis revealed a higher risk to develop dyslipidemia after 1, 3, and 5\u2009years of follow-up among the SMM patients. The MM patients had a higher risk to develop diabetes after 1\u2009year, hypertension after 5\u2009years, and dyslipidemia after 1, 3, and 5\u2009years of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data demonstrate that patients with SMM and those with MM are more prone to develop various components of metabolic syndrome, and they stress the importance of following-up metabolic syndrome components in both groups of patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-06976-1","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T05:02:44Z","timestamp":1590814964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma"],"prefix":"10.1186","volume":"20","author":[{"given":"Efrat","family":"Markus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Trestman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoel","family":"Angel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Sofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Mittelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naftali","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4742-878X","authenticated-orcid":false,"given":"Elena","family":"Izkhakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,30]]},"reference":[{"key":"6976_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jgo.2016.04.001","volume":"8","author":"TM Wildes","year":"2017","unstructured":"Wildes TM, Campagnaro E. Management of multiple myeloma in older adults: gaining ground with geriatric assessment. J Geriat Oncol. 2017;8:1\u20137.","journal-title":"J Geriat Oncol"},{"key":"6976_CR2","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1182\/blood-2015-03-575365","volume":"126","author":"G Bianchi","year":"2015","unstructured":"Bianchi G, Richardson PG, Anderson KC. Promising therapies in multiple myeloma. Blood. 2015;126:300\u201310.","journal-title":"Blood"},{"key":"6976_CR3","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"R Fonseca","year":"2017","unstructured":"Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, et al. Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia. 2017;31:1915\u201321.","journal-title":"Leukemia"},{"key":"6976_CR4","first-page":"39","volume":"11","author":"EM Maiese","year":"2018","unstructured":"Maiese EM, Evans KA, Chu B, Irwin DE. Temporal trends in survival and healthcare costs in patients with multiple myeloma in the United States. Am Health Drug Benefits. 2018;11:39\u201346.","journal-title":"Am Health Drug Benefits"},{"key":"6976_CR5","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564\u20139.","journal-title":"N Engl J Med"},{"key":"6976_CR6","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962\u201372.","journal-title":"Blood"},{"key":"6976_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.100","volume":"6","author":"A Ravindran","year":"2016","unstructured":"Ravindran A, Bartley AC, Holton SJ, Gonsalves WI, Kapoor P, Siddiqui MA, et al. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J. 2016;6:e486.","journal-title":"Blood Cancer J"},{"key":"6976_CR8","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:538\u201348.","journal-title":"Lancet Oncol"},{"key":"6976_CR9","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","volume":"125","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar SV, Landgren O, Mateos M-V, Kyle R, Remstein E, Therneau T, et al. Smoldering multiple myeloma. Blood. 2015;125:3069\u201375.","journal-title":"Blood"},{"key":"6976_CR10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMc1106428","volume":"365","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med. 2011;365:474\u20135.","journal-title":"N Engl J Med"},{"key":"6976_CR11","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1182\/blood-2011-06-362830","volume":"119","author":"JJ Castillo","year":"2012","unstructured":"Castillo JJ, Mull N, Reagan JL, Nemr S, Mitri J. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. Blood. 2012;119:4845\u20133850.","journal-title":"Blood"},{"key":"6976_CR12","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/cncr.22921","volume":"110","author":"A Badros","year":"2007","unstructured":"Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer. 2007;110:1042\u20139.","journal-title":"Cancer"},{"key":"6976_CR13","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","volume":"144","author":"PG Richardson","year":"2009","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144:895\u2013903.","journal-title":"Br J Haematol"},{"key":"6976_CR14","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJMoa021423","volume":"348","author":"EE Calle","year":"2003","unstructured":"Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625\u201338.","journal-title":"N Engl J Med"},{"key":"6976_CR15","doi-asserted-by":"publisher","first-page":"178962","DOI":"10.1155\/2014\/178962","volume":"2014","author":"S Jin","year":"2014","unstructured":"Jin S, Wu Y, Deng S, Zhang J, Chen XQ. Oxidants and antioxidants in metabolic syndrome and cancer. Oxidative Med Cell Longev. 2014;2014:178962.","journal-title":"Oxidative Med Cell Longev"},{"key":"6976_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1600-0609.2012.01828.x","volume":"89","author":"Y-S Chou","year":"2012","unstructured":"Chou Y-S, Yang C-F, Chen H-S, Yang S-H, Yu Y-B, Hong Y-C, et al. Pre-existing diabetes mellitus in patients with multiple myeloma. Eur J Haematol. 2012;89:320\u20137.","journal-title":"Eur J Haematol"},{"key":"6976_CR17","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1158\/1055-9965.EPI-06-0007","volume":"15","author":"BCH Chiu","year":"2006","unstructured":"Chiu BCH, Gapstur SM, Greenland P, Wang R, Dyer A. Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. Cancer Epidemiol Biomark Prev. 2006;15:2348\u201354.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"6976_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2955-0","volume":"16","author":"A Chari","year":"2016","unstructured":"Chari A, Mezzi K, Zhu S, Werther W, Felici D, Lyon AR. Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study. BMC Cancer. 2016;16:1\u201310.","journal-title":"BMC Cancer"},{"key":"6976_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1185\/03007995.2015.1105202","volume":"32","author":"X Song","year":"2016","unstructured":"Song X, Cong Z, Wilson K. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Curr Med Res Opin. 2016;32:95\u2013103.","journal-title":"Curr Med Res Opin"},{"key":"6976_CR20","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1515\/cclm.1987.25.10.675","volume":"25","author":"H Hachem","year":"1987","unstructured":"Hachem H, Favre G, Ghalim N, Puchois P, Fruchart JC, Soula G. Quantitative abnormalities of lipoprotein particles in multiple myeloma. Clin Chem Lab Med. 1987;25:675\u201380.","journal-title":"Clin Chem Lab Med"},{"key":"6976_CR21","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/sj.bmt.1705972","volume":"41","author":"C Annaloro","year":"2008","unstructured":"Annaloro C, Usardi P, Airaghi L, Giunta V, Forti S, Orsatti A, et al. Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41:797\u2013804.","journal-title":"Bone Marrow Transplant"},{"key":"6976_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/bmt.2016.203","volume":"52","author":"Z Defilipp","year":"2017","unstructured":"Defilipp Z, Duarte R, Snowden J, Majhail N, Greenfield D, Miranda J, et al. Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. Bone Marrow Transplant. 2017;52:173\u201382.","journal-title":"Bone Marrow Transplant"},{"key":"6976_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","volume":"86","author":"MA Dimopoulos","year":"2011","unstructured":"Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011;86:23\u201331.","journal-title":"Eur J Haematol"},{"key":"6976_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.h1","volume":"350","author":"KK Tsilidis","year":"2015","unstructured":"Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JPA. Type 2 diabetes and cancer: umbrella review of meta-analyses of observationlal studies. BMJ. 2015;350:1\u201311.","journal-title":"BMJ"},{"key":"6976_CR25","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1093\/aje\/kwv290","volume":"183","author":"R Dankner","year":"2016","unstructured":"Dankner R, Boffetta P, Balicer RD, Boker LK, Sadeh M, Berlin A, et al. Time-dependent risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults. Am J Epidemiol. 2016;183:1098\u2013106.","journal-title":"Am J Epidemiol"},{"key":"6976_CR26","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.2337\/dc10-0666","volume":"33","author":"E Giovannucci","year":"2010","unstructured":"Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674\u201385.","journal-title":"Diabetes Care"},{"key":"6976_CR27","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.2337\/diabetes.52.7.1799","volume":"52","author":"BB Duncan","year":"2003","unstructured":"Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, et al. Low-grade systemic inflammation and the development of type 2 diabetes. Diabetes. 2003;52:1799\u2013805.","journal-title":"Diabetes"},{"key":"6976_CR28","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1001\/jama.286.3.327","volume":"286","author":"AD Pradhan","year":"2001","unstructured":"Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J Am Med Assoc. 2001;286:327\u201334.","journal-title":"J Am Med Assoc"},{"key":"6976_CR29","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(99)01046-6","volume":"353","author":"MI Schmidt","year":"1999","unstructured":"Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, et al. Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): a cohort study. Lancet. 1999;353:1649\u201352.","journal-title":"Lancet"},{"key":"6976_CR30","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2337\/diabetes.51.4.1131","volume":"51","author":"A Festa","year":"2002","unstructured":"Festa A, Agostino RD, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. Diabetes. 2002;51:1131\u20137.","journal-title":"Diabetes"},{"key":"6976_CR31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2337\/diabetes.51.2.455","volume":"51","author":"B Vozarova","year":"2002","unstructured":"Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51:455\u201361.","journal-title":"Diabetes"},{"key":"6976_CR32","doi-asserted-by":"publisher","first-page":"48732","DOI":"10.18632\/oncotarget.8982","volume":"7","author":"L Bieghs","year":"2016","unstructured":"Bieghs L, Johnsen HE, Maes K, Menu E, Van Valckenborgh E, Overgaard MT, et al. The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential. Oncotarget. 2016;7:48732\u201352.","journal-title":"Oncotarget"},{"key":"6976_CR33","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0889-8588(18)30344-7","volume":"6","author":"B Klein","year":"1992","unstructured":"Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am. 1992;6:273\u201384.","journal-title":"Hematol Oncol Clin North Am"},{"key":"6976_CR34","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1365-2141.1993.tb04696.x","volume":"83","author":"G Merlini","year":"1993","unstructured":"Merlini G, Perfetti V, Gobbi PG, Quaglini S, Franciotta DM, Marinone G, et al. Acute phase proteins and prognosis in multiple myeloma. Br J Haematol. 1993;83:595\u2013601.","journal-title":"Br J Haematol"},{"key":"6976_CR35","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1182\/blood.V85.3.765.bloodjournal853765","volume":"85","author":"TT Pelliniemi","year":"1995","unstructured":"Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajam\u00e4ki A, Tienhaara A, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood. 1995;85:765\u201371.","journal-title":"Blood"},{"key":"6976_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1046\/j.1365-2257.2003.00492.x","volume":"25","author":"MG Alexandrakis","year":"2003","unstructured":"Alexandrakis MG, Passam FH, Ganotakis ES, Sfiridaki K, Xilouri I, Perisinakis K, et al. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol. 2003;25:41\u20136.","journal-title":"Clin Lab Haematol"},{"key":"6976_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0014-5793(89)80476-4","volume":"242","author":"JV Castell","year":"1989","unstructured":"Castell JV, G\u00f3mez-Lech\u00f3n MJ, David M, Andus T, Geiger T, Trullenque R, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 1989;242:237\u20139.","journal-title":"FEBS Lett"},{"key":"6976_CR38","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0895-7061(03)00566-1","volume":"16","author":"KC Sung","year":"2003","unstructured":"Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens. 2003;16:429\u201333.","journal-title":"Am J Hypertens"},{"key":"6976_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/sj.jhh.1001785","volume":"19","author":"LE Bautista","year":"2005","unstructured":"Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19:149\u201354.","journal-title":"J Hum Hypertens"},{"key":"6976_CR40","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/00004872-200105000-00004","volume":"19","author":"LE Bautista","year":"2001","unstructured":"Bautista LE, L\u00f3pez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens. 2001;19:857\u201361.","journal-title":"J Hypertens"},{"key":"6976_CR41","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/hr.2016.35","volume":"39","author":"Y Solak","year":"2016","unstructured":"Solak Y, Afsar B, Vaziri ND, Aslan G, Yalcin CE, Covic A, et al. Hypertension as an autoimmune and inflammatory disease. Hypertens Res. 2016;39:567\u201373.","journal-title":"Hypertens Res"},{"key":"6976_CR42","doi-asserted-by":"publisher","DOI":"10.5888\/pcd14.170038","volume":"14","author":"S Hayek","year":"2017","unstructured":"Hayek S, Ifrah A, Enav T, Shohat T. Prevalence, correlates, and time trends of multiple chronic conditions among Israeli adults: estimates from the Israeli National Health Interview Survey, 2014\u20132015. Prev Chronic Dis. 2017;14:E64.","journal-title":"Prev Chronic Dis"},{"key":"6976_CR43","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00277-009-0849-9","volume":"89","author":"B Misselwitz","year":"2010","unstructured":"Misselwitz B, Goede JS, Pestalozzi BC, Schanz U, Seebach JD. Hyperlipidemic myeloma: review of 53 cases. Ann Hematol. 2010;89:569\u201377.","journal-title":"Ann Hematol"},{"key":"6976_CR44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00280-003-0692-y","volume":"53","author":"VT Humgria","year":"2004","unstructured":"Humgria VT, Latrilha MC, Rodrigues DG, Bydlowski SP, Chiattone CS, Maranh\u00e3o RC. Metabolism of a cholesterol-rich micromulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease. Cancer Chemother Pharmacol. 2004;53:51\u201360.","journal-title":"Cancer Chemother Pharmacol"},{"key":"6976_CR45","first-page":"29","volume":"50","author":"RA Kyle","year":"1975","unstructured":"Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975;50:29\u201340.","journal-title":"Mayo Clin Proc"},{"key":"6976_CR46","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00277-007-0375-6","volume":"87","author":"I Yavasoglu","year":"2008","unstructured":"Yavasoglu I, Tombuloglu M, Kadikoylu G, Donmez A, Cagirgan S, Bolaman Z. Cholesterol levels in patients with multiple myeloma. Ann Hematol. 2008;87:223\u20138.","journal-title":"Ann Hematol"},{"key":"6976_CR47","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/ijc.30745","volume":"141","author":"MM Epstein","year":"2017","unstructured":"Epstein MM, Divine G, Chao CR, Wells KE, Feigelson HS, Scholes D, et al. Statin use and risk of multiple myeloma: an analysis from the Cancer research network. Int J Cancer. 2017;141:480\u20137.","journal-title":"Int J Cancer"},{"key":"6976_CR48","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1200\/JCO.2016.68.3482","volume":"34","author":"KM Sanfilippo","year":"2016","unstructured":"Sanfilippo KM, Keller J, Gage BF, Luo S, Wang TF, Moskowitz G, et al. Statins are associated with reduced mortality in multiple myeloma. J Clin Oncol. 2016;34:4008\u201314.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06976-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-06976-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06976-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T19:06:20Z","timestamp":1622315180000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-06976-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,30]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6976"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-06976-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.17585\/v4","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.17585\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.17585\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.17585\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,30]]},"assertion":[{"value":"11 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The institutional review board (Helsinki Medical Ethics Committee) of the TASMC provided approval to conduct this study (approval #0349\u201315-TLV) and waived signed informed consent since the study was based on existing databases.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"489"}}